© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses the significance of the results of a trial exploring entrectinib in patients with ROS1-positive non–small cell lung cancer (NSCLC).